New Drug's brain activity measured in tiny early trial

NCT ID NCT07655518

Recruiting now Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early study tests a new drug called BMS-986521 in 12 healthy adults. Researchers use PET scans to see how much of the drug reaches and attaches to M4 receptors in the brain. The goal is to learn about the drug's action, not to treat any illness. This is a first step before testing in patients with brain disorders.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986521
What this could lead to: If successful, this study could help researchers understand how BMS-986521 interacts with brain receptors, potentially guiding future treatments for conditions like Alzheimer's or schizophrenia.
What could go wrong: This is a very early Phase 1 study with only 12 healthy volunteers. It is designed to measure brain activity, not to treat any disease. The drug may not work as expected or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
RECRUITING

Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.